Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: December 03, 2024)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 28 miles
Kaiser Permanente - Northern California
Vallejo,CA

VISITS: Please contact research site

PHASE: NA

NCT ID: NCT03061305

Molecular Profiling to Select Treatment for Advanced Breast Cancer

Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection (STRATA) Scientific Title

Purpose

To conduct a test of your tumor to determine if there are approved therapies or clinical trials targeting the mutations or biomarkers found in your tumor.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Molecular profiling will be done on your tumor sample at no cost.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A sample of your tumor will be tested for certain mutations and biomarkers. </li> <li class="seamTextUnorderedListItem">Your doctor will be told if there are treatments or clinical trials available for people with the mutations or biomarkers found in your tumor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03061305' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/broad-molecular-profiling-tests' target='_blank'>Breastcancer.org: Broad Molecular Profiling Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/research/octr/our-research/strata-trial' target='_blank'>UNC Lineberger Comprehensive Cancer Center: Study website</a> </li></ul>

NEAREST SITE: 336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05978128

Increasing Breast Cancer Screening Using Advocates and Supporters

Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates Scientific Title

Purpose

To investigate why some people may receive breast cancer screening but not lung cancer screening and to determine if advocates and supporters can increase screening.

Who is this for?

People at least 40 years old who do not currently have cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online educational materials, 3 times within 2 years</li> <li class="seamTextUnorderedListItem">Meet with a patient navigator</li> <li class="seamTextUnorderedListItem">Education materials to share with friends/family on benefits of breast cancer screening</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer screening with mammography is widely accepted and commonly used.</li> <li class="seamTextUnorderedListItem">Advocates and supporters of lung cancer screening may increase the willingness to receive this screening.</li> <li class="seamTextUnorderedListItem">This trial also includes lung cancer screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05978128' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 4 visits

PHASE: NA

NCT ID: NCT05704062

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy Scientific Title

Purpose

To study if MRI scans can earlier and more accurately predict and evaluate response to neoadjuvant (before surgery) chemotherapy.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans, 4 times over the course of chemotherapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like chemotherapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies. </li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan is a type of scan that uses a very strong magnet and no radiation or x-ray energy to take very detailed pictures of parts of the body.</li> <li class="seamTextUnorderedListItem">MRI scans are often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment to measure the tumor size changes in response to treatment and plan for surgery.</li> <li class="seamTextUnorderedListItem">MRI scans are used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment.</li> <li class="seamTextUnorderedListItem">You will receive 4 MRI scans: before treatment, after the first treatment cycle, midway through treatment, and at the end of treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City,UT

VISITS: Coincides with surgery

PHASE: II

NCT ID: NCT05464082

Predict, Prevent, and Treat Early Metastatic Recurrence of HR Low, HER2-/HER2 Low or Triple Negative Breast Cancer

Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple Negative Breast Cancer Scientific Title

Purpose

To study ways to predict, prevent, and treat early metastatic recurrence.

Who is this for?

People with stage I, stage II, or stage III hormone receptor (ER and/or PR) low, HER2 negative (HER2-) or HER2 low or triple negative (ER-, PR-, HER2-) breast cancer. You must have not yet received treatment and be planning to receive surgery and chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Precision oncology is treatment based on specific information from your tumor.</li> <li class="seamTextUnorderedListItem">The tumor samples will be used to complete tests to determine which treatments may be most effective.</li> <li class="seamTextUnorderedListItem">If your cancer comes back (recurrence) after surgery and chemotherapy, your doctor will receive information to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+ and ISH-.</li> <li class="seamTextUnorderedListItem">In this trial, hormone receptor (HR) low is defined as 1-10% of cells that are ER+ and PR+.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05464082' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/precision-medicine-breast-cancer/about/pac-20385240' target='_blank'>Mayo Clinic: What is Precision Oncology?</a> </li></ul>

NEAREST SITE: 650 miles
Mayo Clinic Hospital Arizona
Phoenix,AZ

VISITS: 1 visit every 3 months

PHASE: II

NCT ID: NCT05721248

Safely Stopping Anti-HER2 Targeted Therapy for People with Advanced HER2+ Breast Cancer Who Are Exceptional Responders

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer Scientific Title

Purpose

To study if anti-HER2 targeted therapy can be safely stopped in people with HER2 positive metastatic breast cancer that have had an exceptional response to treatment.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer that has not progressed in the last 3 years during treatment with any anti-HER2 targeted therapy as a first line of therapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You can choose to participate in 1 of 2 groups: Group 1: Choose to Continue Anti-HER2 Treatment <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Continue anti-HER2 treatment</li> <li class="seamTextUnorderedListItem">Visits, monthly for 2-3 months, then every 3 months</li> <li class="seamTextUnorderedListItem">Imaging scans, every 3 months</li> </ul> Group 2: Choose to Stop Anti-HER2 Treatment <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop anti-HER2 treatment</li> <li class="seamTextUnorderedListItem">Visits, monthly for 2-3 months, then every 3 months</li> <li class="seamTextUnorderedListItem">Imaging scans, every 3 months</li> </ul> followed 1 year later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop treatment indefinitely if no progression</li> <li class="seamTextUnorderedListItem">Imaging scans (surveillance), every 3-6 months for 10 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You can choose which group you would like to participate in.</li> <li class="seamTextUnorderedListItem">Exceptional response is considered cancer progression being controlled for 3 years or more since starting anti-HER2 targeted treatment.</li> <li class="seamTextUnorderedListItem">This study is also studying whether blood samples that may contain traces of DNA from cancer, known as circulating tumor DNA (ctDNA), are able to help identify which people can successfully stop treatment without a change in their cancer.</li> <li class="seamTextUnorderedListItem">If you have estrogen receptor positive (ER+) breast cancer, you will continue hormone therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05721248' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials2/detail/22-655/' target='_blank'>Dana-Farber Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mbc-exceptional-responder/' target='_blank'>Metastatic Trial Talk: Why Do Some People Have an Exceptional Response When Being Treated for MBC?</a> </li></ul>

NEAREST SITE: 1539 miles
Mayo Clinic Health System Mankato
Mankato,MN

VISITS: At least 2 visits

PHASE: NA

NCT ID: NCT05662345

Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Scientific Title

Purpose

To study whether the CELLSEARCH® Circulating Tumor Cell Test helps doctors make treatment decisions and determine response to treatment.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or triple negative (ER-, PR-, HER2-) breast cancer. If you have ER+, HER2- breast cancer, you must have received at least 1 line of therapy for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample for CELLSEARCH® Circulating Tumor Cell Test</li> </ul> followed within 1.5 years by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging scans, at least 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">The CELLSEARCH® Circulating Tumor Cell Test can detect CTCs in your blood to help your doctor make treatment decisions and determine your response to treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05662345' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cellsearchctc.com/about-cellsearch/what-is-cellsearch-ctc-test' target='_blank'>Menarini Silicon Biosystems: CELLSEARCH® Circulating Tumor Cell Test</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06055881

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS) Scientific Title

Purpose

To study if radiation therapy can delay treatment changes and if circulating tumor cells (CTCs) can help guide treatment options.

Who is this for?

Women with stage IV (metastatic) breast cancer who have been receiving their first line of therapy for metastatic disease for at least 1 year or have been receiving their second or later line of therapy for at least 6 months. You must have 1-3 sites of oligoprogressive disease that have not received radiation and must not have triple negative breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery or stereotactic body radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">In this trial, CTCs may be used to help you and your doctor guide treatment options.</li> <li class="seamTextUnorderedListItem">Oligoprogressive disease refers to progression of only a few sites of metastasis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055881' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20555625' target='_blank'>Mayo Clinic: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794' target='_blank'>Mayo Clinic: Stereotactic Body Radiotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20071218' target='_blank'>Breastcancer.org: Circulating Tumor Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oligometastatic-breast-cancer/' target='_blank'>Metastatic Trial Talk: What is Oligometastatic Breast Cancer?</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05049746

Decision Making Tool for Older Women with Stage I-III Breast Cancer

Identifying Decision Making Needs for Older Adult Women With Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy Scientific Title

Purpose

To study how a decision making tool affects how older women make breast cancer treatment decisions.

Who is this for?

Women at least 65 years old with stage I, stage II, or stage III breast cancer who have made a decision within the last 3 months about whether or not to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Decision making tool with educational materials</li> <li class="seamTextUnorderedListItem">Interviews and questionnaires, over 1-2 hours</li> <li class="seamTextUnorderedListItem">Discussion and shared decision making questionnaire, over 15-30 mins</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interviews and questionnaires, over 1-2 hours</li> <li class="seamTextUnorderedListItem">Discussion and shared decision making questionnaire, over 15-30 mins</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This decision making tool includes personalized information about the risks and benefits of chemotherapy.</li> <li class="seamTextUnorderedListItem">This tool is designed to promote shared decision making between you and your healthcare provider.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05049746' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/making-treatment-decisions/making-decisions.html' target='_blank'>American Cancer Society: Understanding Your Options and Making Treatment Decisions</a> </li><li class='seamTextUnorderedListItem'><a href='https://mghdecisionsciences.org/about-us-home/shared-decision-making/' target='_blank'>Massachusetts General Hospital: Shared Decision Making</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05755984

3D Printed Breast Models for Surgery Decision Making for Women with Stage 0-III Breast Cancer

3D Printed Breast Models in the Surgical Management of Breast Cancer Scientific Title

Purpose

To study if providing a 3D printed model of the breast helps people make decisions about surgery compared to standard of care breast imaging scans.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive surgery at MD Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care breast imaging</li> <li class="seamTextUnorderedListItem">Discussion during surgical consultation</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3D printed model of your breast</li> <li class="seamTextUnorderedListItem">Discussion during surgical consultation</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The 3D printed model may be better for helping people decide between mastectomy and lumpectomy.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05755984' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02918474

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Decision Making Tool for Contralateral Prophylactic Mastectomy Scientific Title

Purpose

To learn more about an online decision support tool that helps you and your doctor discuss whether or not you should have a contralateral prophylactic mastectomy (removal of breast that does not have cancer).

Who is this for?

Women recently diagnosed with DCIS or stage I, stage II, or stage III breast cancer and are seeing a surgeon at MD Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete a questionnaire before and after using the decision support tool.
If you take part in this study, you will complete a questionnaire about the decision support tool.
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02918474' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1667 miles
Marshfield Medical Center-EC Cancer Center
Eau Claire,WI

VISITS: 2 visits in 1 month

PHASE: NA

NCT ID: NCT04549571

Web Tools to Improve Treatment Decision Making and Communication for Women with Stage 0-III Breast Cancer

Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHARES) Scientific Title

Purpose

To compare the ability of 2 web tools to improve treatment decision making and communication with doctors.

Who is this for?

Women with newly diagnosed stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not yet received surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Improved Web Tool <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use iCanDecide - Emotional Support Enhancement (ESE) website before surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> followed 9-12 months later: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview, by phone (optional)</li> </ul> Group 2: Standard Web Tool <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use iCanDecide - Standard (S) website before surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> followed 9-12 months later: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview, by phone (optional)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">iCanDecide - Emotional Support Enhancement (ESE) is an improved patient-facing breast cancer treatment decision tool that supports the management of worry, distress, and anxiety.</li> <li class="seamTextUnorderedListItem">iCanDecide - Standard (S) is a patient-facing breast cancer treatment decision tool that does not include emotional support.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04549571' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1737 miles
Siteman Cancer Center
Saint Louis,MO

VISITS: 2 visits within 2 months

PHASE: NA

NCT ID: NCT03524430

RDA Test to Determine Response to Treatment Before Surgery for Stage I-III Breast Cancer

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) Scientific Title

Purpose

To study how well the RNA Disruption Assay (RDA) test can predict response to treatment during neoadjuvant (before surgery) treatment.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 2 months</li> <li class="seamTextUnorderedListItem">RNA Disruption Assay (RDA) test using biopsy samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tests that can predict who will respond and who will not respond to chemotherapy early during treatment are important for the best outcomes.</li> <li class="seamTextUnorderedListItem">The RNA Disruption Assay (RDA) test uses a biopsy sample to test for a biomarker that tells doctors whether chemotherapy is killing cancer cells.</li> <li class="seamTextUnorderedListItem">If the RDA test tells the doctor that chemotherapy is not working, the doctor may consider switching your treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03524430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://rnadiagnostics.com/rda/' target='_blank'>RNA Diagnostics: The RDA Test</a> </li></ul>

NEAREST SITE: 1761 miles
University of Wisconsin School of Medicine and Public Health
Madison,WI

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04573231

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT Scientific Title

Purpose

To evaluate prostate specific membrane antigen (PSMA) expression in breast cancer to determine people most likely to benefit from anti-androgen therapies.

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-), androgen receptor positive (AR+) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>

NEAREST SITE: 1832 miles
Medical College of Wisconsin
Milwaukee,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06383026

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Understanding Breast Cancer Risk and Screening in Transgender and Gender-Diverse Persons Through a Pilot Breast Cancer Screening Program Scientific Title

Purpose

To study the breast cancer screening perceptions and experiences of transgender and gender-diverse people and understand factors that make breast cancer screening more difficult.

Who is this for?

Transgender and gender-diverse people at least 30 years old who have received gender-affirming hormone therapy. You must not have a history of breast cancer or a known genetic mutation that increases your risk for breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram</li> <li class="seamTextUnorderedListItem">Whole breast ultrasound</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transgender and gender-diverse people may experience barriers and non-equitable treatment by healthcare professionals that make receiving breast cancer screening more difficult.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06383026' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1849 miles
Orchard Healthcare Research Inc.
Skokie,IL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05935384

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation Scientific Title

Purpose

To collect information to develop a Guardant360 blood test that can measure treatment response.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) who have received 0-1 lines of therapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 blood test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 is a blood test that identifies genomic biomarkers and mutations to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">This trial is collecting information to develop a future version of Guardant360 that can measure treatment response.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05935384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/tumor-marker-tests' target='_blank'>Breastcancer.org: Breast Cancer Biomarkers and Biomarker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/' target='_blank'>Guardant Health: Guardant360 Test Information Page</a> </li></ul>

NEAREST SITE: 1853 miles
University of Illinois at Chicago Hospital and Ambulatory Clinics
Chicago,IL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04378751

Promoting Genetic Counseling Among African American Women at High Risk for Breast Cancer

Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer Scientific Title

Purpose

To study the ability of a genetic counseling video to promote genetic counseling among African American women at high risk for breast cancer.

Who is this for?

African American women at least 25 years old who are at high risk for developing breast cancer and have not received genetic counseling. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a genetic counseling video</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Review a genetic counseling informational brochure</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic counseling can identify people at high risk for breast cancer and can help personalize prevention.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04378751' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing for Breast Cancer Risk</a> </li><li class='seamTextUnorderedListItem'><a href='https://medicine.wustl.edu/news/african-american-breast-cancer-patients-less-likely-to-receive-genetic-counseling-testing/' target='_blank'>Washington University School of Medicine: African American Women and Genetic Counseling</a> </li></ul>

NEAREST SITE: 1857 miles
University of Chicago Medical Center
Chicago,IL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04541381

Pharmacogenomics Testing to Make Chemotherapy Dosing Decisions for People with Breast Cancer

PhOCus: Implementation of Pharmacogenomic Testing in Oncology Care Scientific Title

Purpose

To study if pharmacogenomics testing, a type of genetic testing, helps doctors make chemotherapy dosing decisions and decreases chemotherapy side effects.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive chemotherapy. You must be receiving care at The University of Chicago Medical Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive chemotherapy</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide DNA samples for pharmacogenomics testing, after chemotherapy treatment</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide DNA samples for pharmacogenomics testing</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive chemotherapy based on pharmacogenomics testing results</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Doctors leading the study will collect your genetic information using pharmacogenomics/genotyping, a type of genetic testing.</li> <li class="seamTextUnorderedListItem">Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, your doctor will use your test results to make dosing decisions/changes to your chemotherapy treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04541381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://nigms.nih.gov/education/fact-sheets/Pages/pharmacogenomics.aspx#:~:text=Pharmacogenomics%20(sometimes%20called%20pharmacogenetics)%20is,best%20suited%20for%20each%20person.' target='_blank'>National Institutes of Health: Pharmacogenomics</a> </li></ul>

NEAREST SITE: 1906 miles
Clinical Site
Covington,LA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05697198

OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine Scientific Title

Purpose

To study the ability of the OmniSeq Test to detect biomarkers and mutations compared to a liquid biopsy.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and/or tissue samples for OmniSeq Test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The OmniSeq Test is a genomic test that detects biomarkers and mutations for many types of cancer.</li> <li class="seamTextUnorderedListItem">The OmniSeq Test may help your doctor select your treatment based on detected biomarkers and mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05697198' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncology.labcorp.com/cancer-care-team/test-menu/omniseq-insight' target='_blank'>Labcorp: OmniSeq Test</a> </li></ul>

NEAREST SITE: 1985 miles
Baptist Health Clinical Research
Elizabethtown,KY

VISITS: At least 2 visits over 6-8 weeks

PHASE: NA

NCT ID: NCT05037825

How the Gut Microbiome May Affect Immunotherapy in Stage I-IV Triple Negative Breast Cancer

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors Scientific Title

Purpose

To study the gut microbiome to see if it can determine if immunotherapy will be effective.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) triple negative breast cancer (ER-, PR- and HER2-) who are about to begin treatment with a checkpoint inhibitor (immunotherapy). You must speak English or Spanish. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 blood tests over 6-8 weeks</li> <li class="seamTextUnorderedListItem">2 stool samples over 6-8 weeks</li> <li class="seamTextUnorderedListItem">Questionairres (in English or Spanish)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome may help determine if immunotherapy will be effective. </li> <li class="seamTextUnorderedListItem">By studying the microbiome, researchers may also be able to determine if changing the microbiome through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, can help the immune system fight cancer.</li> <li class="seamTextUnorderedListItem">Immunotherapies are drugs that trigger the immune system to see, go after, and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) are a type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05037825' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04526587

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Scientific Title

Purpose

To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>

NEAREST SITE: 2314 miles
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem,NC

VISITS: 3 visits within 2 years

PHASE: NA

NCT ID: NCT05309655

Impact of Hormone Therapy on Heart Health in Women with Stage I-III Breast Cancer

The Cardiac Outcomes With Near-Complete Estrogen Deprivation (CROWN) Study Scientific Title

Purpose

To study the effect of near complete estrogen deprivation (NCED) hormone therapy on heart health.

Who is this for?

Premenopausal women 18-55 years old with stage I, stage II, or some stage III breast cancer. If you have hormone receptor positive (ER+ and/or PR+) breast cancer, you must be planning to receive or receiving treatment with an aromatase inhibitor or selective estrogen receptor degrader (SERD) hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans, 3 times</li> <li class="seamTextUnorderedListItem">CT scans, 2 times</li> <li class="seamTextUnorderedListItem">Electrocardiogram (ECG or EKG), 2 times</li> <li class="seamTextUnorderedListItem">Blood tests, 3 times</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Near complete estrogen deprivation (NCED) is treatment with an aromatase inhibitor or selective estrogen receptor degrader (SERD) hormone therapy.</li> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">An electrocardiogram (ECG) test records electrical signals in your heart.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with hormone receptor negative (ER- and/or PR-) breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05309655' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dukehealth.org/clinical-trials/directory/pro00110774' target='_blank'>Duke Health: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/side-effects/heart-health' target='_blank'>Living Beyond Breast Cancer: Heart Health</a> </li></ul>

NEAREST SITE: 2378 miles
UNC Lineberger Comprehensive Cancer Center
Chapel Hill,NC

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05978557

Tumor Samples From Surgery to Predict Response to Treatment for Brain Metastasis

A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors Scientific Title

Purpose

To study a new way to predict response to treatment using tumor samples from brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of tumor samples during brain surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will use tumor samples from brain surgery to determine which types of treatments are most likely to be effective.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05978557' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2385 miles
Duke Cancer Institute
Durham,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06275126

Online Tool for Making Surgery Decisions for Young Women With Stage 0-III Breast Cancer

Optimizing Surgical Decisions in Young Adults With Breast Cancer (CONSYDER) Scientific Title

Purpose

To understand and improve the breast surgery decision-making process for young women newly diagnosed with breast cancer.

Who is this for?

Women up to 44 years old with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not yet received surgery. Your breast cancer must not have recurred (come back). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Based on when you enroll, you will take part in 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online CONSYDER decision tool</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> People in Group 1 will have access to the online CONSYDER decision tool after 6 months.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CONSYDER is an online tool that is designed to provide useful information to young people with breast cancer. </li> <li class="seamTextUnorderedListItem">CONSYDER was also designed to improve communication between young women and their surgeons with the purpose of helping patients make surgical decisions.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06275126' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2402 miles
UNC Rex Healthcare
Raleigh,NC

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03769415

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer Scientific Title

Purpose

To study if genomic testing affects which line of therapy doctors suggest people with metastatic breast cancer receive.

Who is this for?

People with metastatic (stage IV) breast cancer who have received no more than one line of therapy for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PAM50 (Prosigna®) testing of your breast tumor, 1 time</li> <li class="seamTextUnorderedListItem">Results of the PAM50 test will be given to your treating doctor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care for treating metastatic breast cancer is to make treatment decisions based on clinical subtype. </li> <li class="seamTextUnorderedListItem">Clinical subtypes include hormone-positive (ER+ and/or PR+), HER2-positive (HER2+), and triple-negative (ER-, PR-, HER2-).</li> <li class="seamTextUnorderedListItem">The PAM50 (Prosigna®) is a genomic test approved for use in some women with early-stage breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor. This gives your doctor a genetic subtype of your tumor. </li> <li class="seamTextUnorderedListItem">This trial is studying whether knowing a tumor's genetic subtype will affect how doctors treat people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Making treatment decisions based on genetic subtypes is not the standard of care.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03769415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/octr/our-team/' target='_blank'>Study Coordinator Information: Terri Eubanks</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/genomic-tumor-testing/' target='_blank'>Metastatic Trial Talk: Genomic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prosigna.com' target='_blank'>Veracyte Test Information Page: PAM50 (Prosigna®)</a> </li></ul>

NEAREST SITE: 2434 miles
Medstar Georgetown University Hospital
Washington,DC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05334732

Sisters Informing Sisters Coaching Program to Improve Treatment Adherence in Black Women with Stage I-III Breast Cancer

Improving Communication and Adherence in Black Breast Cancer Survivors Scientific Title

Purpose

To study if the Sisters Informing Sisters coaching program increases adherence to treatment.

Who is this for?

Black women with newly diagnosed stage I, stage II, or stage III breast cancer who received surgery less than 1 month ago and are planning to begin chemotherapy or hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sisters Informing Sisters coaching program</li> <li class="seamTextUnorderedListItem">Workbook </li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">National Cancer Institute treatment information booklet</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sisters Informing Sisters is a peer-based, culturally-tailored, positive role-modeling coaching program.</li> <li class="seamTextUnorderedListItem">In Sisters Informing Sisters, Black cancer survivors educate Black women with breast cancer about how to communicate with their doctors and the importance of completing treatment.</li> <li class="seamTextUnorderedListItem">The National Cancer Institute treatment information booklet provides women with national-level recommendations regarding treatment recommendations.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05334732' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://richmondmagazine.com/life-style/health/going-for-the-moon-shot/' target='_blank'>Richmond Magazine: Sisters Informing Sisters</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/latest-news/breast-cancer-death-rates-are-highest-for-black-women-again.html#:~:text=Black%20women%20have%20the%20lowest%205%2Dyear%20relative%20breast%20cancer,and%20every%20breast%20cancer%20subtype.&text=There%20is%20a%206%25%20t' target='_blank'>American Cancer Society: Black Women and Breast Cancer</a> </li></ul>

NEAREST SITE: 2564 miles
University of Vermont Medical Center
Burlington,VT

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06280300

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases Scientific Title

Purpose

To compare how well multi-disciplinary care and standard care work for managing symptoms and understanding outcomes.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Multi-disciplinary care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Care for people with brain metastases involves complex medical decision making and requires input for multiple groups (disciplines).</li> <li class="seamTextUnorderedListItem">Multi-disciplinary care includes medical oncology, neurosurgery, radiation oncology, neuro-oncology, and palliative care.</li> <li class="seamTextUnorderedListItem">This process may look different for different patients.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06280300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2569 miles
Columbia University Irving Medical Center
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05351424

Video or Brochure to Educate Non-English Speaking Latinx Women with Breast Cancer About Radiation Therapy and Cancer Clinical Trials

Audiovisual Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology Scientific Title

Purpose

To develop educational materials to prepare Latinx Spanish-speaking people for radiation therapy and to improve understanding about participating in cancer clinical trials.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are Spanish speakers of Latinx background (from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry) and who are planning to receive radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to Group 1 or 2: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about radiation therapy.</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about radiation therapy.</li> </ul> You will also be randomly assigned to Group 3 or 4: Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about cancer clinical trials.</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about cancer clinical trials.</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low understanding of health information and language barriers can lead to low trial enrollment in minority and/or non-English speakers and produce trial results that don't reflect this population.</li> <li class="seamTextUnorderedListItem">Culturally appropriate audiovisual materials may improve knowledge about radiotherapy and increase chances of completing treatment, as well as improve knowledge about clinical trials and increase enrollment in Latinx/Spanish-speaking people.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05351424' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astro.org/Patient-Care-and-Research/Provider-Resources/Patient-Brochures' target='_blank'>American Society for Radiation Oncology: Patient Brochures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/patient-education/cancer-treatment-research-studies' target='_blank'>National Cancer Institute: Taking Part in Cancer Research Studies</a> </li></ul>

NEAREST SITE: 2569 miles
Columbia University Irving Medical Center/NYP
New York,NY

VISITS: 3 times within 7 months

PHASE: NA

NCT ID: NCT04824027

Ultrasound Scan to Predict Response to Chemotherapy Before Surgery for Women with Stage I-III Breast Cancer

Predicting Response to Neoadjuvant Chemotherapy Using Harmonic Motion Imaging in Women With Breast Cancer Scientific Title

Purpose

To investigate the role of a new type of imaging scan, harmonic motion imaging (HMI), for prediction of breast cancer response to chemotherapy given before surgery (neoadjuvant).

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) scan, 3 times within 7 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Early detection of lack of response to chemotherapy given before surgery (neoadjuvant) could allow doctors to stop ineffective treatment and start a new treatment to achieve better tumor response and overall survival.</li> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) is a novel, non-invasive ultrasound scan.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04824027' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2569 miles
Herbert Irving Comprehensive Cancer Care Center
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05146297

Clinical Trial Education and Navigation for People with Stage I-IV Breast Cancer

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials Scientific Title

Purpose

To study whether a list of clinical trials, clinical trial educational materials, and clinical trial patient navigators (CTPN) increase participation in clinical trials, especially in the Black, Indigenous, and People of Color (BIPOC) community.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">List of matched clinical trials</li> <li class="seamTextUnorderedListItem">Clinical trial educational materials</li> <li class="seamTextUnorderedListItem">Clinical trial patient navigator (CTPN)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a list of matched clinical trials and educational materials designed to inform and empower you to consider clinical trials.</li> <li class="seamTextUnorderedListItem">You will also work with a clinical trial patient navigator (CTPN) to further educate you about clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is available in English and Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05146297' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2574 miles
Montefiore Medical Center
Bronx,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03694756

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer Scientific Title

Purpose

To study the ability of TMEM-MRI, an experimental type of MRI scan, to detect breast cancer cells.

Who is this for?

People with a breast mass that is suspected to be breast cancer, or people with stage I, stage II, or some stage III breast cancer who have not yet received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TMEM-MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Biopsy (if you have not yet received one)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Tumor Microenvironment of Metastasis - Magnetic Resonance Imaging (TMEM-MRI) scans are an experimental type of MRI scan that can detect tumor areas that are more likely to travel to other sites in the body.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may be useful to identify tumors with a higher chance of coming back (recurrence) after treatment.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may also be useful for studying the response to neoadjuvant (before surgery) treatment such as chemotherapy and hormone therapy.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03694756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 2591 miles
University of Miami
Miami,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05959291

Free-HER: Stopping Maintenance Anti-HER2 Targeted Therapy for People with Metastatic HER2+ Breast Cancer and No Evidence of Disease

Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer Scientific Title

Purpose

To study if people who stop taking anti-HER2 targeted therapy for maintenance will stay in complete remission.

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who have been in complete remission, also called no evidence of disease (NED), for at least 3 years and have been receiving anti-HER2 targeted therapy for at least 3 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop taking anti-HER2 targeted therapy</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Imaging scans</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is a type of anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Complete remission is also known as no evidence of disease (NED).</li> <li class="seamTextUnorderedListItem">Blood tests will measure circulating tumor DNA (ctDNA), which are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">You will continue to receive routine monitoring, blood tests, and imaging scans.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05959291' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: What is Anti-HER2 Targeted Therapy?</a> </li></ul>

NEAREST SITE: 2693 miles
Beth Israel Deaconess Medical Center
Boston,MA

VISITS: At least 1 visit

PHASE: NA

NCT ID: NCT06011434

nline Tool to Help Women 75+ Years Old Make Mammogram Decisions

Testing a Conversation Aid on Mammography Screening for Clinicians and Women 75 and Older in Practice Scientific Title

Purpose

To develop and test an online tool to help primary care doctors discuss the pros and cons of mammograms with older women and help older women make mammogram decisions.

Who is this for?

Women 75-89 years old whose last mammogram was between 6 months and 2.5 years ago and had a normal result. You must not have a history of breast cancer. Your primary care provider must be at Beth Israel Deaconess Medical Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Appointment with primary care doctor</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 2 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The usefulness of mammograms in women older than 75 years varies according to the woman's life expectancy, risk of breast cancer, and preferences.</li> <li class="seamTextUnorderedListItem">Current guidelines recommend that primary care doctors talk to women aged 75 years and older and reach a shared decision about mammograms.</li> <li class="seamTextUnorderedListItem">The online <q>Decide Together</q> conversation tool is designed to be used by a primary care doctor and patient for shared decision making and to provide information and education on the benefits and harms of mammograms.</li> <li class="seamTextUnorderedListItem">You must have a family member willing to participate in the study. Your family member will attend the appointment with your primary care provider.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06011434' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2698 miles
Mass General/North Shore Center for Outpatient Care
Danvers,MA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05837598

Improving Cancer Care and Mental Health Care for People with Newly Diagnosed Stage I-IV Breast Cancer

Adapting the Tumor Board Model for Mental Illness and Cancer: A Single Arm Pilot Trial Scientific Title

Purpose

To study whether a virtual tumor board can improve cancer care and mental health care.

Who is this for?

People with newly diagnosed stage I, stage II, stage III, or stage IV (metastatic) breast cancer. You must also have one of the following mental illnesses: schizophrenia, bipolar disorder, or major depressive disorder. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Assessment of your needs, values, mental health symptoms, and barriers to care</li> <li class="seamTextUnorderedListItem">Recommendations from the virtual tumor board to help you receive the care you need</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tumor board is a group of doctors and other health care providers that meets regularly at the hospital to discuss cancer cases and share knowledge.</li> <li class="seamTextUnorderedListItem">A virtual cancer and mental health tumor board may help people access the cancer and mental health care they need.</li> <li class="seamTextUnorderedListItem">The tumor board will notify your doctor with treatment and care recommendations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05837598' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/blog/2017-07/what-tumor-board-expert-qa' target='_blank'>ASCO: What is a Tumor Board?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mhanational.org/cancer-and-mental-health' target='_blank'>Mental Health America: Cancer and Mental Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/lung-cancer-treating-mental-health-longer-survival' target='_blank'>National Cancer Institute: Study Links Mental Health Treatment to Improved Cancer Survival</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04496739

Tools to Help Women Make Decisions About Medication to Prevent Breast Cancer

Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) Scientific Title

Purpose

To compare the ability of a web-based decision support tool and standard educational materials to help women make decisions about medication to prevent breast cancer.

Who is this for?

Women 35-74 years old with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) who do not have a history of breast cancer and have not taken medication to prevent breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials about breast cancer risk and prevention, virtual</li> <li class="seamTextUnorderedListItem">Decision support tool with action plan and breast cancer risk navigation, virtual</li> <li class="seamTextUnorderedListItem">Interview, virtual, 1 time (optional)</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials about breast cancer risk and prevention, virtual</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Treatment called chemoprevention can reduce the risk of developing breast cancer in people with high-risk breast conditions such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS).</li> <li class="seamTextUnorderedListItem">Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) are hormone therapy drugs that can be used for chemoprevention. However, these treatments can have side effects.</li> <li class="seamTextUnorderedListItem">Decision support tools are designed to improve informed choice about breast cancer chemoprevention.</li> <li class="seamTextUnorderedListItem">If you are in group 2, the action plan will summarize your breast cancer risk profile, risks and benefits of SERMs and AIs, and personal preferences for chemoprevention.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04496739' target='_blank'>ClinicalTrials.gov</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT03452774

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Scientific Title

Purpose

To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05810025

RealRisks Online Program for Breast Cancer Risk Assessment

Integrating EHR and Patient-generated Health Data for Breast Cancer Risk Assessment and Decision Support in a Diverse Multiethnic Population Scientific Title

Purpose

To study how the RealRisks program promotes understanding of breast cancer risk and prevention and perceptions by users of their risk for breast cancer.

Who is this for?

Women, age 35-74 years old, at high risk for breast cancer but who have not been diagnosed with breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of the RealRisks program, online</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RealRisks is a web-based patient-centered program designed to improve: 1) accurate understanding of breast cancer risk; 2) knowledge about drugs that could prevent breast cancer, and 3) making choices based on information. RealRisks includes audio and modules about breast cancer risk (including interactive games on risk communication) and drugs that could prevent breast cancer. </li> <li class="seamTextUnorderedListItem">Through RealRisks, study investigators will collect information on breast cancer risk factors to calculate a person's breast cancer risk score and also factors that influence decision-making about prevention. </li> <li class="seamTextUnorderedListItem">RealRisks generates an action plan for patients summarizing their personalized breast cancer risk and preference for prevention.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05810025' target='_blank'>ClinicalTrials.gov</a> </li></ul>

Browse Trials

Narrow my choices:

Molecular Profiling to Select Treatment for Advanced Breast Cancer

Contact Research Sites

Increasing Breast Cancer Screening Using Advocates and Supporters

Contact Research Sites

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Contact Research Sites

Predict, Prevent, and Treat Early Metastatic Recurrence of HR Low, HER2-/HER2 Low or Triple Negative Breast Cancer

Contact Research Sites

Safely Stopping Anti-HER2 Targeted Therapy for People with Advanced HER2+ Breast Cancer Who Are Exceptional Responders

Contact Research Sites

Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer

Contact Research Sites

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Contact Research Sites

Decision Making Tool for Older Women with Stage I-III Breast Cancer

Contact Research Sites

3D Printed Breast Models for Surgery Decision Making for Women with Stage 0-III Breast Cancer

Contact Research Sites

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Contact Research Sites

Web Tools to Improve Treatment Decision Making and Communication for Women with Stage 0-III Breast Cancer

Contact Research Sites

RDA Test to Determine Response to Treatment Before Surgery for Stage I-III Breast Cancer

Contact Research Sites

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Contact Research Sites

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Contact Research Sites

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

Contact Research Sites

Promoting Genetic Counseling Among African American Women at High Risk for Breast Cancer

Contact Research Sites

Pharmacogenomics Testing to Make Chemotherapy Dosing Decisions for People with Breast Cancer

Contact Research Sites

OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer

Contact Research Sites

How the Gut Microbiome May Affect Immunotherapy in Stage I-IV Triple Negative Breast Cancer

Contact Research Sites

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

Contact Research Sites

Impact of Hormone Therapy on Heart Health in Women with Stage I-III Breast Cancer

Contact Research Sites

Tumor Samples From Surgery to Predict Response to Treatment for Brain Metastasis

Contact Research Sites

Online Tool for Making Surgery Decisions for Young Women With Stage 0-III Breast Cancer

Contact Research Sites

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

Contact Research Sites

Sisters Informing Sisters Coaching Program to Improve Treatment Adherence in Black Women with Stage I-III Breast Cancer

Contact Research Sites

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Contact Research Sites

Video or Brochure to Educate Non-English Speaking Latinx Women with Breast Cancer About Radiation Therapy and Cancer Clinical Trials

Contact Research Sites

Ultrasound Scan to Predict Response to Chemotherapy Before Surgery for Women with Stage I-III Breast Cancer

Contact Research Sites

Clinical Trial Education and Navigation for People with Stage I-IV Breast Cancer

Contact Research Sites

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

Contact Research Sites

Free-HER: Stopping Maintenance Anti-HER2 Targeted Therapy for People with Metastatic HER2+ Breast Cancer and No Evidence of Disease

Contact Research Sites

nline Tool to Help Women 75+ Years Old Make Mammogram Decisions

Contact Research Sites

Improving Cancer Care and Mental Health Care for People with Newly Diagnosed Stage I-IV Breast Cancer

Contact Research Sites

Tools to Help Women Make Decisions About Medication to Prevent Breast Cancer

Contact Research Sites

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

Contact Research Sites

RealRisks Online Program for Breast Cancer Risk Assessment

Contact Research Sites

Connect

Site Map